Disclosures

• We have no relevant financial interests to disclose.
Source: CDC state-reported data (cases and deaths), Unified Testing Dataset, Unified Hospital Dataset.
NUMBER OF NEW CASES AND DEATHS IN THE LAST 7 DAYS

Total Cumulative Cases: 29,113,651
New Cases in Last 7 Days: 464,152
Percent Change from Previous 7 Days: +7.4%

Total Cumulative Deaths: 529,301
New Deaths in Last 7 Days: 10,133
Percent Change from Previous 7 Days: -16.5%

Cases by County in the Week 05MAR2021-11MAR2021

Deaths by County in the Week 05MAR2021-11MAR2021

Missouri data includes a backlog of 81,608 probable cases in the current 7-day window due to the addition of antigen case reporting.
Virginia deaths reported in the current 7-day window contain a significant number of additional deaths that occurred earlier in 2021.
Ohio changed their method of reporting COVID-19 deaths as of 3/2/2021 and will only report twice per week; they will report deaths on the day of death, not the day of report, which could result in a fluctuation in the number of deaths from recent weeks.

No Data
Illinois Cases and Hot Spots

Current Positivity rate
Based on a 7 day rolling average

2.8% ▲
Prior wk.: 2.8%

Tests performed (3/1/2020 - 3/12/2021)
Cumulative tests
3,313,862

Daily tests (7 day rolling average)
11,643 ▲
Prior wk.: 11,615 (0%)

Cases (3/1/2020 - 3/12/2021)
Cumulative cases
248,753

Daily cases (7 day rolling average)
276 ▲
Prior wk.: 275 (0%)
## Variants Update

<table>
<thead>
<tr>
<th>Variant</th>
<th>Reported Cases in US</th>
<th>Number of Jurisdictions Reporting</th>
</tr>
</thead>
<tbody>
<tr>
<td>B.1.1.7</td>
<td>3701</td>
<td>50</td>
</tr>
<tr>
<td>B.1.351</td>
<td>108</td>
<td>23</td>
</tr>
<tr>
<td>P.1</td>
<td>17</td>
<td>10</td>
</tr>
</tbody>
</table>

### Illinois Variant Count

<table>
<thead>
<tr>
<th>Variant Type</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>B.1.1.7</td>
<td>94</td>
</tr>
<tr>
<td>B.1.351</td>
<td>2</td>
</tr>
<tr>
<td>P.1</td>
<td>2</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>98</strong></td>
</tr>
</tbody>
</table>

### Emerging Variant Cases in the United States**†**

Map showing the distribution of variant cases across different states and territories. The map highlights states such as Florida, with the number of cases indicated by color-coded areas. The legend includes filters for the number of cases, with options for 0 to 0, 1 to 100, 101 to 200, 201 to 300, 501 to 600, and 601 to 700 cases.
Vaccine Updates

Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine

- Dramatically lower COVID-19 disease incidence rates observed in individuals fully vaccinated with the Pfizer-BioNTech vaccine, based on real-world data gathered by the Israel Ministry of Health
- Data suggest Pfizer-BioNTech vaccine prevents asymptomatic SARS-CoV-2 infection
  
  Latest data analysis finds unvaccinated individuals were 44 times more likely to develop symptomatic COVID-19 and 29 times more likely to die from COVID-19
- The data from Israel also showed Pfizer's vaccine was highly effective against the coronavirus variant B.1.1.7. The variant made up more than 80% of the specimens tested in the analysis. There weren’t enough infections with the variant B.1351, first discovered in South Africa to determine whether the vaccine is effective against it

Novavax’s Covid-19 Vaccine Effective in U.K. Study

- 2 doses, 3 weeks apart
- 89.7% effective at preventing mild to severe disease 15,000 adults in the U.K.
- 83.4% effective at preventing Covid-19 at 14 days after the first dose
- Efficacy was higher among people infected with the original strain of the virus, at 96.4%, while it was 86.3% effective in those infected with a variant first identified in the U.K. (B.1.1.1.7)
- The second study was in South Africa, overall efficacy of its vaccine was 48.6% in this study.

Our Guests

Anthony Reder, MD
Professor of Neurology

Ayodeji Adegunsoye, MD
Assistant Professor of Medicine, Section of Pulmonary / Critical Care

Royce Lee, MD
Associate Professor of Psychiatry and Behavioral Neuroscience
Questions?